CABALETTA BIO, INC. Operating Income
CABALETTA BIO, INC. (CABA) reported Operating Income of -$52.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-13
- CABALETTA BIO, INC. operating income (loss) for the quarter ending 2026-06-30 was -$52.02M.
- CABALETTA BIO, INC. operating income (loss) for the quarter ending 2026-03-31 was -$44.30M.
- CABALETTA BIO, INC. operating income (loss) for the quarter ending 2025-12-31 was -$42.61M.
- CABALETTA BIO, INC. operating income (loss) for the quarter ending 2025-09-30 was -$46.59M.
- CABALETTA BIO, INC. operating income (loss) for fiscal 2025 was -$172.24M.
- CABALETTA BIO, INC. operating income (loss) for fiscal 2024 was -$125.14M.
- CABALETTA BIO, INC. operating income (loss) for fiscal 2023 was -$74.66M.
- CABALETTA BIO, INC. operating income (loss) for fiscal 2022 was -$54.14M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$52.02M 10-Q · filed 2026-08-13 | -$96.32M 10-Q · filed 2026-08-13 | -$138.93M derived: sum of 3 quarters · filed 2026-08-13 | -$185.52M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$44.30M 10-Q · filed 2026-05-14 | -$86.91M derived: sum of 2 quarters · filed 2026-05-14 | -$133.50M derived: sum of 3 quarters · filed 2026-05-14 | -$179.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$42.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$89.20M derived: sum of 2 quarters · filed 2026-03-23 | -$135.10M derived: sum of 3 quarters · filed 2026-08-13 | -$172.24M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$46.59M 10-Q · filed 2025-11-10 | -$92.49M derived: sum of 2 quarters · filed 2026-08-13 | -$129.63M 10-Q · filed 2025-11-10 | -$163.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$45.91M 10-Q · filed 2026-08-13 | -$83.04M 10-Q · filed 2026-08-13 | -$116.83M derived: sum of 3 quarters · filed 2026-08-13 | -$149.87M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$37.14M 10-Q · filed 2026-05-14 | -$70.92M derived: sum of 2 quarters · filed 2026-05-14 | -$103.97M derived: sum of 3 quarters · filed 2026-05-14 | -$134.25M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$33.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$66.83M derived: sum of 2 quarters · filed 2026-03-23 | -$97.11M derived: sum of 3 quarters · filed 2026-03-23 | -$125.14M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$33.05M 10-Q · filed 2025-11-10 | -$63.33M derived: sum of 2 quarters · filed 2025-11-10 | -$91.36M 10-Q · filed 2025-11-10 | -$114.50M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$30.28M 10-Q · filed 2025-08-07 | -$58.31M 10-Q · filed 2025-08-07 | -$81.46M derived: sum of 3 quarters · filed 2025-08-07 | -$100.12M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$28.03M 10-Q · filed 2025-05-15 | -$51.18M derived: sum of 2 quarters · filed 2025-05-15 | -$69.84M derived: sum of 3 quarters · filed 2025-05-15 | -$85.73M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$23.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$41.81M derived: sum of 2 quarters · filed 2025-03-31 | -$57.70M derived: sum of 3 quarters · filed 2025-03-31 | -$74.66M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$18.67M 10-Q · filed 2024-11-14 | -$34.56M derived: sum of 2 quarters · filed 2024-11-14 | -$51.51M 10-Q · filed 2024-11-14 | -$67.82M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$15.89M 10-Q · filed 2024-08-08 | -$32.85M 10-Q · filed 2024-08-08 | -$49.15M derived: sum of 3 quarters · filed 2024-08-08 | -$60.93M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$16.96M 10-Q · filed 2024-05-15 | -$33.26M derived: sum of 2 quarters · filed 2024-05-15 | -$45.04M derived: sum of 3 quarters · filed 2024-05-15 | -$58.10M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$16.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$28.08M derived: sum of 2 quarters · filed 2024-03-21 | -$41.14M derived: sum of 3 quarters · filed 2024-03-21 | -$54.14M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$11.78M 10-Q · filed 2023-11-09 | -$24.84M derived: sum of 2 quarters · filed 2023-11-09 | -$37.84M 10-Q · filed 2023-11-09 | -$51.73M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$13.06M 10-Q · filed 2023-08-10 | -$26.06M 10-Q · filed 2023-08-10 | -$39.95M derived: sum of 3 quarters · filed 2023-08-10 | -$51.52M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$13.00M 10-Q · filed 2023-05-11 | -$26.89M derived: sum of 2 quarters · filed 2023-05-11 | -$38.45M derived: sum of 3 quarters · filed 2023-05-11 | -$49.60M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$13.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$25.46M derived: sum of 2 quarters · filed 2023-03-16 | -$36.60M derived: sum of 3 quarters · filed 2023-03-16 | -$46.31M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$11.56M 10-Q · filed 2022-11-10 | -$22.71M derived: sum of 2 quarters · filed 2022-11-10 | -$32.42M 10-Q · filed 2022-11-10 | -$41.75M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$11.14M 10-Q · filed 2022-08-11 | -$20.86M 10-Q · filed 2022-08-11 | -$30.19M derived: sum of 3 quarters · filed 2022-08-11 | -$38.60M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$9.71M 10-Q · filed 2022-05-12 | -$19.04M derived: sum of 2 quarters · filed 2022-05-12 | -$27.46M derived: sum of 3 quarters · filed 2022-05-12 | -$35.65M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$9.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$17.75M derived: sum of 2 quarters · filed 2022-03-17 | -$25.94M derived: sum of 3 quarters · filed 2022-03-17 | -$33.83M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$8.42M 10-Q · filed 2021-11-01 | -$16.61M derived: sum of 2 quarters · filed 2021-11-01 | -$24.50M 10-Q · filed 2021-11-01 | -$30.36M derived: sum of 4 quarters · filed 2021-11-01 |
| 2020-06-30 | -$8.19M 10-Q · filed 2021-08-05 | -$16.09M 10-Q · filed 2021-08-05 | -$21.95M derived: sum of 3 quarters · filed 2021-08-05 | -$26.98M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$7.89M 10-Q · filed 2021-05-03 | -$13.76M derived: sum of 2 quarters · filed 2021-05-03 | -$18.79M derived: sum of 3 quarters · filed 2021-05-03 | -$22.59M derived: sum of 4 quarters · filed 2021-05-03 |
| 2019-12-31 | -$5.86M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$10.89M derived: sum of 2 quarters · filed 2021-03-16 | -$14.69M derived: sum of 3 quarters · filed 2021-03-16 | -$18.68M 10-K · filed 2021-03-16 |
| 2019-09-30 | -$5.03M 10-Q · filed 2020-11-10 | -$8.83M derived: sum of 2 quarters · filed 2020-11-10 | -$12.82M 10-Q · filed 2020-11-10 | -$14.89M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | -$3.80M 10-Q · filed 2020-08-06 | -$7.79M 10-Q · filed 2020-08-06 | -$9.86M derived: sum of 3 quarters · filed 2020-08-06 | -$12.94M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | -$3.99M 10-Q · filed 2020-05-12 | -$6.05M derived: sum of 2 quarters · filed 2020-05-12 | -$9.13M derived: sum of 3 quarters · filed 2020-05-12 | |
| 2018-12-31 | -$2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | -$5.14M derived: sum of 2 quarters · filed 2020-03-30 | -$6.19M 10-K · filed 2020-03-30 | |
| 2018-09-30 | -$3.08M 10-Q · filed 2019-12-05 | -$4.13M 10-Q · filed 2019-12-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |